Language:
COFEPRIS will investigate the 63 CANNABIS permits granted in Mexico back on 2018.
April 19, 2023
On October 30, 2018, the Mexican Regulatory Agency (COFEPRIS) published guidelines establishing the criteria for the appraisal of applications of authorizations for the commercialization, exploitation, and importation of products with broad industrial uses that contain cannabis and its derivative in concentrations less than 1% of tetrahydrocannabinol (THC). Afterwards these guidelines were revoked.
Based on those guidelines, COFEPRIS granted 63 authorizations that allowed the commercialization of variety of cannabis-derived products.
Since COFEPRIS´ guidelines lacked the corresponding regulatory or legislative hierarchy the authorizations have been always in a gray zone, recently the Mexican President announced that COFEPRIS will conduct an investigation into the 63 permits granted back in 2018 and eventually revoke the permits based on the lack of legal grounds.
OLIVARES will closely follow developments on the review conducted by the sanitary authority.
FOR FURTHER INFORMATION ON THE CONTENT OF THIS NEWSLETTER, PLEASE CONTACT:
Alejandro Luna F.
Partner
Alejandro Luna joined OLIVARES in 1996 and being made partner in 2005, he has been instrumental to the firm’s IP Litigation, Regulatory, and Administrative Litigation practices. He co-chairs the Life Sciences & Pharmaceutical Law industry group and coordinates the Litigation Department.
Gustavo Alcocer
Partner
Gustavo Alcocer manages the Corporate and Commercial Law Group at OLIVARES, advising domestic and foreign businesses and the owners of those businesses on Mexican and cross-border corporate and commercial transactions.
Armando Arenas
Partner
Armando Arenas joined OLIVARES in 2000 and became a partner in January 2017. He has experience working on a range of IP matters, including consulting and litigation on trademark, patent, unfair competition, trade dress protection, and misleading advertising cases before the Mexican Institute of Industrial Property (IMPI), Federal Court of Tax and Administrative Affairs (FCTA), Federal Circuit Courts (FCC) and the Supreme Court of Justice (SCJ) Regulatory Affairs and Public Acquisitions.
ASSOCIATES
WHO CAN BE FOUND AT THE FOLLOWING NUMBER:
+52(55) 5322 3000
Newsletters - Life Science
- Regulatory certainty for Biosimilars in Mexico. February 22, 2024
- Mexico. COVID-19 vaccine approvals update December 15, 2023
- Mexico: The Supreme Court of Justice authorized the industrial use of cannabis. December 8, 2021
- Alejandro Luna’s Interview On Innovation And Biotechnology January 18, 2013
- Mexico starts the New Year with new guidelines to apply for drugs and medical devices marketing authorizations. January 10, 2024
- New guidelines for good manufacturing practices concerning medical devices in Mexico. January 12, 2022
- New prohibition of vapes and electronic cigarettes in Mexico. June 2, 2022
- Civil Court in Mexico Acquits Holder of Pharmaceutical Patent Rights to Compensate Damages Claimed by Alleged Infringer. September 7, 2021